Ozempic / Wegovy (GLP-1) Suicidal Ideation & Psychiatric Injury Litigation
Case Overview
As GLP-1 receptor agonist medications like Ozempic (semaglutide) and Wegovy surged to blockbuster status for diabetes management and weight loss, a parallel wave of personal injury litigation emerged alleging that Novo Nordisk concealed serious psychiatric risks associated with the drugs. Plaintiffs — including patients and their families — allege that after starting semaglutide therapy, they experienced severe depression, suicidal thoughts, self-harm ideation, and other debilitating psychiatric episodes that resolved only after discontinuing the medication. The European Medicines Agency (EMA) opened a formal review of GLP-1 drugs and suicidality in 2023, and the FDA updated labeling requirements, lending regulatory credibility to the plaintiffs' core claims.
The lawsuits allege that Novo Nordisk knew or should have known about the psychiatric risks from clinical trial data and post-market surveillance but failed to adequately warn prescribing physicians and patients. Claims include strict products liability for failure to warn, negligent misrepresentation, and negligence per se. With semaglutide prescriptions in the U.S. exceeding 9 million annually and the drug's extraordinary cultural prominence, this litigation is expected to grow into one of the largest pharmaceutical mass torts since the opioid crisis. Attorneys are coordinating filings in federal courts with potential MDL consolidation actively discussed.
Who May Qualify
Patients who were prescribed and used Ozempic (semaglutide) or Wegovy and subsequently experienced suicidal ideation, severe depression, self-harm behaviors, or related psychiatric injuries, as well as the families of those who suffered fatal outcomes potentially linked to these side effects.
Frequently Asked Questions
Can I sue Novo Nordisk if Ozempic caused suicidal thoughts?
Yes, you may have a claim if you or a loved one experienced suicidal ideation, severe depression, or other psychiatric side effects after using Ozempic or Wegovy. Attorneys are actively reviewing cases and the litigation is growing rapidly.
Did the FDA warn about Ozempic causing suicidal thoughts?
The FDA and European regulators launched reviews of GLP-1 drugs including semaglutide in 2023 following reports of psychiatric events. The FDA subsequently updated labeling, and plaintiffs argue the warnings came far too late given what Novo Nordisk knew from clinical data.
Is there an Ozempic psychiatric injury MDL?
As of 2025, federal cases are being coordinated and MDL consolidation is under active consideration. Multiple filings in the Eastern District of Pennsylvania and other courts are being tracked for potential centralization before a single federal judge.